receiving salvage SBRT, met inclusion criteria (median follow up of 21 months). No significant differences (p¼0.77) were observed between maximum point doses to BP, SCV, and SCA. Within one year post-SBRT, two patients (3%) developed BPX (grade 2); both patients had exceeded 32 Gy to the BP and were treated with salvage SBRT. No patient treated with definitive SBRT (91%) developed BP, despite 17 of these exceeding recommended maximum doses. Conclusion: No BPX was observed for patients that exceeded a maximum dose of 32 Gy to the BP, unless they were treated as salvage SBRT. This suggests higher doses to the BP may be considered when clinically required for definitive SBRT. However, salvage SBRT may require more conservative BP constraints than used in the definitive setting.
P1. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The Impact of Spironolactone on the Lung Injury Induced by Concomitant Trastuzumab and Thoracic Radiotherapy G. Yavas, 1 C. Yavas, 1 E. Celik, 2 E. Sen, 3 O. Ata, 4 D. Yuce, 5 R. Elsurer-Afsar 6 1 Radiation Oncology, Selcuk University, Konya/TR, 2 Pathology, Selcuk University, Konya/TR, 3 Medical Oncology, Selcuk University, Konya/TR, 4 Medical Oncology, Selcuk University, Konya/TR, 5 Preventive Oncology, Hacettepe University, Ankara/TR, 6 Nephrology, Selcuk University, Konya/TR Background: Radiation-induced lung injury (RILI) is a potentially lifethreatening and dose-limiting side effect of thoracic irradiation. Trastuzumab (T), a monoclonal antibody directed against HER2, improves overall survival in patients with HER2 positive breast cancer. T concurrently with radiation thus increases the antitumor effect of radiation. There are same clinical evidences in the literature that T also radiosensibilizes human healthy tissues and in this way it could increase the toxicity of the treatment. The incidence of T-induced pneumonitis is 0.4e0.6%. Although infrequent; pulmonary toxicity due to T may be life-threatening. Aldosterone, which is a physiological activator of MR, is partially responsible for increases in the extracellular matrix turnover, as observed in fibrosis of the cardiac, kidney and lung tissues, and exerts its effects primarily on lung epithelium. Spironolactone (S), an aldosterone receptor antagonist, may have the ability to ameliorate pulmonary fibrosis.We hypothesized that S would be effective in the treatment of both RT and T-induced lung injury by correcting pulmonary fibrosis Method: This study included 80 female Wistar-Albino rats (250-300 g); use of which was approved by the Ethical Committee. Rats were divided into eight groups: group (G) 1 was control group; G2, G3 and G4 were RT, S and T groups; G5, G6, G7 and G8 were RT+T, T+S, RT+S and RT+T+S groups respectively. RT was applied under general anesthesia with intraperitoneally administered 90 mg/kg ketamine hydrochloride and 10 mg/kg xylazine. A single dose of 15 Gy was applied to the both lungs. T (6 mg/kg) was administered intraperitoneally and S (80 mg/kg) was administered by oral gavage. Rats were sacrificed via cervical dislocation at 6 th hour, 21 st day and 100 th day after RT and the lung samples were taken for microscopical examination. Result: By 100 th days of RT inflammation score, lung fibrosis score and TGF-expression were significantly different within study groups (p values were 0.002, 0.001 and 0.043 respectively). Inflammation score of G8 was significantly lower than inflammation scores of G2 and G5 (p values: G2-G8¼ 0.004, and G5-G8¼0.022). Inflammation score of G2 was significantly higher than G7 (p¼0.028). There were significant differences regarding to fibrosis scores between G2-G8 (p¼0.015), G2-G7 (p¼0.017) and G5-G8 (p¼0.011). TGF-b expression was higher in both G2 and G5 when compared to G8 (p ¼ 0.038). Conclusion: Our results suggested that S is an effective treatment option for improving radiation-induced pulmonary fibrosis. These findings should be clarified with further preclinical and clinical studies.
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Accelerated Hypofractionated Radiotherapy for Central Lung Tumors Unsuitable for Stereotactic Body Radiotherapy Or Concurrent CRT K.L. Zeng, 1 I. Poon, 1 Y. Ung, 1 L. Zhang, 2 P. Cheung 1 1 Sunnybrook Odette Cancer Centre, Toronto/CA, 2 Macrostat Inc., Toronto/CA Background: In our institution, accelerated hypofractionated radiotherapy is a treatment option for 1) stage I lung non-small cell lung cancer (NSCLC) patients whose tumors are too bulky or central for SBRT; and 2) select stage II-III NSCLC patients not candidates for concurrent CRT. The purpose of this project was to review the clinical outcomes of a large single institutional experience of treating such patients with a dose of 60 Gy in 15 fractions in an era when SBRT was routinely used in clinical practice for early stage lung cancer. Method: Central tumors were defined as the gross target volume being in contact with mainstem bronchi, trachea, esophagus, great vessels, or heart. All patients who received 60 Gy in 15 fractions treated between 2008 and 2017 were reviewed. Competing risk analysis was used to calculate the cumulative incidence of local failure (LF), regional failure (RF), and distant failure (DF). Kaplan-Meier methodology was used to calculate overall survival (OS). Univariate analyses were used to look for potential predictive factors. Result: Eighty-nine patients were treated. Median follow-up was 24.0 months (range: 6.1-94.2 months). Median age was 79.4 years and most tumors were adenocarcinoma (n¼47, 52.8%), followed by squamous cell carcinoma (n¼31, 34.8%). Thirty patients (33.7%) had stage I disease, 47 patients (52.8%) had stage II-III disease, and 12 patients (13.5%) had stage 4 disease (mostly oligometastatic). Cumulative incidence of LF was 15.3% at 2 years. In those with stage I-III disease, cumulative incidence of RF and DF were 12.9%, and 28.5%, respectively at 2-years. OS was 74.9% at 2 years, with a median OS of 39.4 months for those with stage I-III disease. In the subset with stage II-III disease, median OS was 38.1 months and 2 year OS was 67.7%. Tumor stage, histology, EGFR mutation status, and location were not statistically significant predictors for any outcomes, although tumor size >3.5cm was borderline significant in predicting for a higher cumulative incidence of LF (subdistribution hazard ratio ¼ 2.726; 95% confidence interval 0.995-7.469; p¼0.051). The most common toxicity was radiation pneumonitis (n¼6, 6.4%). The cumulative incidence of any grade 3 toxicity was 10.8% at 1 year. There were no deaths or hospitalizations directly attributed to treatment. Background: Lobectomy by video-assisted thoracoscopic surgery (VATS) is preferred over thoracotomy in patients with early-stage nonsmall cell lung cancer (NSCLC). However, controversy still exists regarding the quality of the lymph node dissection accomplished using
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